STOCK TITAN

Shattuck Labs to Report Second Quarter 2021 Financial Results and Provide Corporate Update on August 11, 2021

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary

Shattuck Labs, Inc. (NASDAQ: STTK), a clinical-stage biotechnology company, is set to provide a corporate and financial update for Q2 2021 on August 11, 2021, at 4:30 p.m. ET. The earnings call can be accessed via phone and will be available in archived format for up to 90 days afterward. Shattuck focuses on bi-functional fusion proteins to treat cancer and autoimmune diseases, with lead programs SL-172154 and SL-279252 currently in Phase 1 trials. The company leverages its proprietary ARC® platform for innovative therapies.

Positive
  • Shattuck's lead program SL-172154 is currently in Phase 1 trial, targeting CD47 immune checkpoint.
  • The collaboration with Takeda Pharmaceuticals for SL-279252 indicates potential for broader market access.
Negative
  • None.

AUSTIN, TX and DURHAM, NC, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, will host a webcast and conference call to provide a corporate and financial update for the second quarter of 2021 on Wednesday, August 11, 2021, at 4:30 p.m. ET.

The live call may be accessed by dialing (833) 614-1555 (domestic) or (516) 575-8754 (international) and entering the conference code: 7172288. The live and archived webcast will be available on the Events & Presentations section of the Company’s website. A replay of the webcast will be archived for up to 90 days following the presentation date.

About Shattuck Labs, Inc.
Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck’s proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company’s lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.

The Company intends to use the investor relations portion of its website as a means of disclosing material non-public information and for complying with disclosure obligations under Regulation FD.

Investor Contact:
Conor Richardson
Senior Director, Finance & Investor Relations
Shattuck Labs, Inc.
InvestorRelations@shattucklabs.com

Media Contact:
Stephanie Ascher
Managing Director
Stern Investor Relations, Inc.
Stephanie.Ascher@sternir.com


FAQ

What is the date for Shattuck Labs' Q2 2021 earnings call?

Shattuck Labs will host its Q2 2021 earnings call on August 11, 2021, at 4:30 p.m. ET.

How can I access the Shattuck Labs Q2 2021 earnings call?

The earnings call can be accessed by dialing (833) 614-1555 domestically or (516) 575-8754 internationally.

What are Shattuck Labs' lead programs currently in clinical trials?

Shattuck Labs' lead programs SL-172154 and SL-279252 are both in Phase 1 clinical trials.

What is Shattuck Labs' focus regarding biopharmaceuticals?

Shattuck Labs focuses on developing bi-functional fusion proteins for treating cancer and autoimmune diseases.

Shattuck Labs, Inc.

NASDAQ:STTK

STTK Rankings

STTK Latest News

STTK Stock Data

52.99M
41.34M
13.41%
74.68%
4.59%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
AUSTIN